Key result
UT antagonism suppresses U-II reactivity, showing potential to improve vascular function in diabetic aortic models.
Why the study?
Endothelial buffering normally restrains U-II signaling, but this protection is diminished in diabetes mellitus, contributing to vascular dysfunction, and direct comparisons of selective UT antagonists under diabetic conditions remain limited.
Do selective UT antagonists (Urantide and Palosuran) reduce U-II-induced vasoconstriction in aortae from diabetic and non-diabetic rats?
Do selective UT antagonists (Urantide and Palosuran) reduce U-II-induced vasoconstriction in aortae from diabetic and non-diabetic rats?
UT receptor antagonists Urantide and Palosuran effectively suppress U-II-induced vasoconstriction in diabetic rat aortae, suggesting therapeutic potential for diabetic vasculopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for UT antagonism in diabetic vasculopathy; prospective human studies needed before clinical adoption.
BACKGROUND: UT receptors. Endothelial buffering normally restrains U-II signaling, but this protection is diminished in diabetes mellitus, contributing to vascular dysfunction. Selective UT antagonists such as Urantide (peptidic) and Palosuran (non-peptidic) are promising, yet direct comparisons under diabetic conditions remain limited. OBJECTIVE: To assess the effects of Urantide and Palosuran on U-II-induced vasoconstriction in aortae from non-diabetic and diabetic rats with intact and denuded endothelium. METHODS: M) were generated in the presence or absence of Urantide or Palosuran (1 µM). RESULTS: Endothelial loss nearly doubled U-II contractions in non-diabetic aorta and unmasked hyperreactivity in diabetic vessels. Urantide abolished efficacy, while Palosuran attenuated both efficacy and potency, with pronounced inhibition in diabetic denuded rings. CONCLUSION: UT antagonism effectively suppresses U-II reactivity through distinct pharmacological profiles, highlighting therapeutic potential in diabetic vasculopathy.
No takes yet. Share an insight, caveat, or question.
Abdulfatah et al. (2026) studied Diabetes mellitus. Urantide and Palosuran vs. Absence of antagonists was evaluated on U-II-induced vasoconstriction. Urantide abolished U-II contraction efficacy, while Palosuran attenuated both efficacy and potency, with pronounced inhibition in diabetic denuded aortic rings.
Synapse has enriched 10 related papers. Consider them for comparative context: